Browse by author
Lookup NU author(s): Professor Graham Jackson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2021 Informa UK Limited, trading as Taylor & Francis Group.Introduction: Myeloma is the second most common hematological cancer, with 5800 cases per year diagnosed in the UK. Despite improved treatment it is still considered non-curable, although the median survival has increased from 3 to 8 years over the past 20 years. Treatment involves the use of induction therapy and consolidation with autologous stem cell transplant (ASCT) in patients deemed fit enough. Further attempts to improve outcomes include the use of maintenance therapy. Areas covered: This review details all trials in which lenalidomide has been used as maintenance following ASCT. PubMed searches included randomized control trials, observational cohort, reviews, and meta-analysis. Expert opinion: Lenalidomide is a well-tolerated, oral agent that is associated with increased overall and progression free survival when used as maintenance following ASCT. Its use in this setting is FDA and EMA approved and is standard of care in Europe and North America. The early link between lenalidomide and second hematological cancers appears to be associated with use in combination with melphalan. There is an increase in non-melanoma skin cancers and solid tumors in the elderly but this has minimal impact on mortality. Lenalidomide use as part of combination maintenance is underway and may further improve outcomes.
Author(s): Jones JR, Pawlyn C, Jackson GH
Publication type: Article
Publication status: Published
Journal: Expert Opinion on Drug Safety
Year: 2021
Volume: 20
Issue: 10
Pages: 1137-1145
Online publication date: 29/06/2021
Acceptance date: 16/06/2021
ISSN (print): 1474-0338
ISSN (electronic): 1744-764X
Publisher: Taylor and Francis Ltd.
URL: https://doi.org/10.1080/14740338.2021.1945578
DOI: 10.1080/14740338.2021.1945578
Altmetrics provided by Altmetric
